# The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL

> **NCT07514169** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Large B-Cell Lymphoma (LBCL)

## Interventions

- **DRUG:** Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen

## Key facts

- **NCT ID:** NCT07514169
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514169, "The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07514169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*